Vanguard Group Inc Akero Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,529,628 shares of AKRO stock, worth $244 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,529,628
Previous 4,230,644
7.07%
Holding current value
$244 Million
Previous $171 Million
41.13%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
92.4MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$364 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$309 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$301 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$296 Million4.49% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.51MShares$243 Million0.03% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.5B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...